REPORTING OF INFORMED CONSENT, STANDARD OF CARE AND POST-TRIAL OBLIGATIONS IN GLOBAL RANDOMIZED INTERVENTION TRIALS: A SYSTEMATIC SURVEY OF REGISTERED TRIALS

被引:22
作者
Cohen, Emma R. M.
O'Neill, Jennifer M. [4 ]
Joffres, Michel [3 ]
Upshur, Ross E. G. [5 ]
Mills, Edward [1 ,2 ]
机构
[1] BC Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada
[2] Rhodes Univ, ZA-6140 Grahamstown, South Africa
[3] Simon Fraser Univ, Fac Hlth Sci, Grad Programs, Burnaby, BC V5A 1S6, Canada
[4] Royal Coll Phys & Surg, Ctr Learning Practice, Ottawa, ON, Canada
[5] Univ Toronto, Joint Ctr Bioeth, Toronto, ON, Canada
关键词
Africa; benefit sharing; bioethics; clinical trials; developing world; developing world bioethics; HIV; AIDS; DEVELOPING-COUNTRIES; CLINICAL-TRIALS; DEBATE; HIV;
D O I
10.1111/j.1471-8847.2008.00233.x
中图分类号
B82 [伦理学(道德学)];
学科分类号
010105 [伦理学];
摘要
Objective: Ethical guidelines are designed to ensure benefits, protection and respect of participants in clinical research. Clinical trials must now be registered on open-access databases and provide details on ethical considerations. This systematic survey aimed to determine the extent to which recently registered clinical trials report the use of standard of care and post-trial obligations in trial registries, and whether trial characteristics vary according to setting. Methods: We selected global randomized trials registered on http://www.clinicaltrials.gov and http://www.controlled-trials.com. We searched for intervention trials of HIV/AIDS, malaria, and tuberculosis from 9 October 2004, the date of the most recent version of the Helsinki Declaration, to 10 April 2007. Results: We collected data from 312 trials. Fifty-eight percent (58%, 95% CI = 53 to 64) of trial protocols report informed consent. Fifty-eight percent (58%, 95% CI = 53 to 64) of trials report active controls. Almost no trials (1%, 95% CI = 0.5 to 3) mention post-trial provisions. Most trials measure surrogate outcomes. Twenty percent (20%, 95% CI = 16 to 25) of trials measure patient-important outcomes, such as death; and the odds that these outcomes are in a low income country are five times greater than for a developed country (odds ratio (OR) 5.03, 95% CI = 2.70 to 9.35, p = < 0.001). Pharmaceutical companies are involved in 28% (CI = 23 to 33) of trials and measure surrogate outcomes more often than nonpharmaceutical companies (OR 2.45, 95% CI = 1.18 to 5.09, p = 0.31). Conclusion: We found a large discrepancy in the quality of reporting and approaches used in trials in developing settings compared to wealthier settings.
引用
收藏
页码:74 / 80
页数:7
相关论文
共 27 条
[2]
[Anonymous], 2002, INT ETH GUID BIOM RE
[3]
[Anonymous], 1994, Kendalls Advanced Theory of Statistics, Volume I: Distribution Theory
[4]
[Anonymous], 2005, UNIVERSAL DECLARATIO
[5]
Reflections and recommendations on research ethics in developing countries [J].
Benatar, SR .
SOCIAL SCIENCE & MEDICINE, 2002, 54 (07) :1131-1141
[6]
*DEP HHS, 2005, FDAMA SECT 113 STAT
[7]
Evans S, 2005, TEMPLE INT COMP LAW, V19, P477
[8]
Freedom House, 2007, GLOB PRESS FREED 200
[9]
Clinical trials registries: A reform that is past due [J].
Gold, JL ;
Studdert, DM .
JOURNAL OF LAW MEDICINE & ETHICS, 2005, 33 (04) :811-820
[10]
Ethical review of health research: a perspective from developing country researchers [J].
Hyder, AA ;
Wali, SA ;
Khan, AN ;
Teoh, NB ;
Kass, NE ;
Dawson, L .
JOURNAL OF MEDICAL ETHICS, 2004, 30 (01) :68-72